These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28182759)

  • 1. Established patterns of animal study design undermine translation of disease-modifying therapies for Parkinson's disease.
    Zeiss CJ; Allore HG; Beck AP
    PLoS One; 2017; 12(2):e0171790. PubMed ID: 28182759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease modification in Parkinson's disease.
    Henchcliffe C; Severt WL
    Drugs Aging; 2011 Aug; 28(8):605-15. PubMed ID: 21812497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonhuman primate models of Parkinson's disease.
    Emborg ME
    ILAR J; 2007; 48(4):339-55. PubMed ID: 17712221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methodological Rigor in Preclinical Cardiovascular Studies: Targets to Enhance Reproducibility and Promote Research Translation.
    Ramirez FD; Motazedian P; Jung RG; Di Santo P; MacDonald ZD; Moreland R; Simard T; Clancy AA; Russo JJ; Welch VA; Wells GA; Hibbert B
    Circ Res; 2017 Jun; 120(12):1916-1926. PubMed ID: 28373349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stem cell therapy for Parkinson's disease using non-human primate models.
    Chen ZZ; Niu YY
    Zool Res; 2019 Sep; 40(5):349-357. PubMed ID: 31343853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.
    Johnston TM; Fox SH
    Curr Top Behav Neurosci; 2015; 22():221-35. PubMed ID: 25158623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigating trial design variability in trials of disease-modifying therapies in Parkinson's disease: a scoping review protocol.
    Zeissler ML; Boey T; Chapman D; Rafaloff G; Dominey T; Raphael KG; Buff S; Pai HV; King E; Sharpe P; O'Brien F; Carroll CB
    BMJ Open; 2023 Dec; 13(12):e071641. PubMed ID: 38070893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trial designs used to study neuroprotective therapy in Parkinson's disease.
    Lang AE; Melamed E; Poewe W; Rascol O
    Mov Disord; 2013 Jan; 28(1):86-95. PubMed ID: 22927060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
    Lang AE; Espay AJ
    Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein nonhuman primate models of Parkinson's disease.
    Marmion DJ; Kordower JH
    J Neural Transm (Vienna); 2018 Mar; 125(3):385-400. PubMed ID: 28434076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonhuman Primates and Translational Research: Progress, Opportunities, and Challenges.
    Harding JD
    ILAR J; 2017 Dec; 58(2):141-150. PubMed ID: 29253273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review and meta-analysis of clinical effectiveness of self-management interventions in Parkinson's disease.
    Pigott JS; Kane EJ; Ambler G; Walters K; Schrag A
    BMC Geriatr; 2022 Jan; 22(1):45. PubMed ID: 35016613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-modifying strategies for Parkinson's disease.
    Kalia LV; Kalia SK; Lang AE
    Mov Disord; 2015 Sep; 30(11):1442-50. PubMed ID: 26208210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why have we failed to achieve neuroprotection in Parkinson's disease?
    Olanow CW; Kieburtz K; Schapira AH
    Ann Neurol; 2008 Dec; 64 Suppl 2():S101-10. PubMed ID: 19127580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonhuman Primate Models of Neurodegenerative Disorders.
    Emborg ME
    ILAR J; 2017 Dec; 58(2):190-201. PubMed ID: 28985333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of nonhuman primate models in the development of cell-based therapies for Parkinson's disease.
    Vermilyea SC; Emborg ME
    J Neural Transm (Vienna); 2018 Mar; 125(3):365-384. PubMed ID: 28326445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
    Fox SH; Brotchie JM
    Prog Brain Res; 2010; 184():133-57. PubMed ID: 20887873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.